^
Association details:
| Biomarker: | EGFR L861R |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor
Excerpt:
Biopsy of the progressing pulmonary lymph node (containing 70% tumor cells) revealed a novel EGFR amplification (log ratio 1.21) associated with an activating mutation of EGFR located in a hot spot codon of p.Leu861Arg (p.L861R, allele frequency 53%) activating mutation on exon 21.
DOI:
10.1016/j.jtho.2015.08.001
